Metabolites were historically thought to be little more than sources of energy and molecular building blocks in cells, but recent research has started to unveil the regulatory potential of metabolites. Our approach revolutionizes the discovery of new allosteric protein-metabolite interactions to develop novel small molecule therapeutics.
Identification and structural characterization of the binding sites on proteins that are engaged by metabolites can deepen our understanding of how a variety of cellular and molecular processes are governed. Atavistik has built a robust mass spectrometry-based screening platform using cutting edge informatics to discover and characterize novel regulatory sites. We are combining this knowledge with the state-of-the-art artificial intelligence-machine learning integrated structure-based drug design tools to discover new therapeutics.
Atavistik Metabolite Protein Screening (AMPS)
It has been historically challenging to systematically assess the vast number of potential metabolite-protein interactions and allosteric regulators of drug targets. Atavistik Bio has overcome this challenge using the Atavistik Metabolite Protein Screening (AMPS) platform, which is an enhanced and industrialized version of a technology developed at the University of Utah.
By leveraging our optimized AMPS platform and computational approaches, we aim to evaluate metabolite-protein interactions by screening proteins with our proprietary metabolite library to determine where binding sites with biological relevance might exist and build an extensive protein-metabolite database map (the “Interactome”) to reveal unique insights into the crosstalk between metabolite-protein pathways that were previously thought to be unrelated. Utilizing advanced informatics tools, our deep expertise in chemistry and computationally rich structure-based drug design, we will be able to identify and understand the role of these interactions across important biological and disease-relevant pathways to drive the discovery of novel therapeutics.